## IN THE CLAIMS:

Please amend the claims as follows:

Cancel claims 1-36, without prejudice.

Add new claims 37-74 as follow:

- 1-36. (Cancelled)
- 37. (New) A Smurf polypeptide comprising greater than 70% homology with an amino acid sequence depicted in SEQ ID NO:2.
- 38. (New) The Smurf polypeptide of claim 37 comprising an amino acid sequence depicted in SEQ ID NO:2.
- 39. (New) The Smurf polypeptide of claim 37 comprising greater than 90% homology with an amino acid sequence depicted in SEQ ID NO:2.
- 40. (New) The Smurf polypeptide of claim 37 or 39 comprising a mutation corresponding to C710A.
- 41. (New) A Smurf polypeptide comprising greater than 70% homology with an amino acid sequence depicted in SEQ ID NO:4.
- 42. (New) The Smurf polypeptide of claim 41 comprising an amino acid sequence depicted in SEQ ID NO:4.
- 43. (New) The Smurf polypeptide of claim 41 comprising greater than 90% homology with an amino acid sequence depicted in SEQ ID NO:4.
- 44. (New) The Smurf polypeptide of claim 41 or 43 comprising a mutation corresponding to C716A.
- 45. (New) A nucleic acid which encodes SEQ ID NO:2.
- 46. (New) The nucleic acid of claim 45 comprising a nucleotide sequence depicted in SEQ ID NO:1.

- 47. (New) A nucleic acid comprising at least about 70% homology with a nucleotide sequence depicted in SEQ ID NO:1.
- 48. (New) The nucleic acid of claim 47 comprising at least about 80% homology with a nucleotide sequence depicted in SEQ ID NO:1.
- 49. (New) The nucleic acid of claim 47 or 48 comprising a mutation corresponding to C710A.
- 50. (New) An oligonucleotide or nucleic acid that specifically hybridizes to a nucleic acid which encodes SEQ ID NO:2 under highly stringent conditions.
- 51. (New) An isolated nucleic acid which encodes SEQ ID NO:4.
- 52. (New) The nucleic acid of claim 51 comprising a nucleotide sequence depicted in SEQ ID NO:3.
- 53. (New) A nucleic acid comprising at least about 70% homology with a nucleotide sequence depicted in SEQ ID NO:3.
- 54. (New) The nucleic acid of claim 53 comprising at least about 80% homology with a nucleotide sequence depicted in SEQ ID NO:3.
- 55. (New) The nucleic acid of claim 53 or 54 comprising a mutation corresponding to C716A.
- 56. (New) An oligonucleotide or nucleic acid that specifically hybridizes to a nucleic acid which encodes SEQ ID NO:4 under highly stringent conditions.
- 57. (New) A vector comprising a nucleic acid which encodes SEQ ID NO:2.
- 58. (New) A host cell comprising the vector of claim 57.
- 59. (New) A vector comprising a nucleic acid which encodes SEQ ID NO:4.
- 60. (New) A host cell comprising the vector of claim 59.

- 61. (New) A method for producing an amino acid sequence depicted in SEQ ID NO:2 which comprises growing a host cell which expresses the amino acid sequence depicted in SEQ ID NO:2.
- 62. (New) A method for producing an amino acid sequence depicted in SEQ ID NO:4 which comprises growing a host cell which expresses the amino acid sequence depicted in SEQ ID NO:4.
- 63. (New) A transgenic non-human animal which expresses an amino acid sequence depicted in SEQ ID NO:2.
- 64. (New) A transgenic non-human animal which expresses an amino acid sequence depicted in SEQ ID NO:4.
- 65. (New) A method for inhibiting a bone morphogenic protein or tumor growth factor-beta activation pathway in a cell which comprises expressing an isolated nucleic acid which encodes SEQ ID NO:2.
- 66. (New) A method for promoting a bone morphogenic protein or tumor growth factor-beta activation pathway in a cell which comprises suppressing endogenous expression of an amino acid sequence depicted in SEQ ID NO:2.
- 67. (New) A method for inhibiting a bone morphogenic protein or tumor growth factor-beta activation pathway in a cell which comprises expressing an isolated nucleic acid which encodes SEQ ID NO:4.
- 68. (New) A method for promoting a bone morphogenic protein or tumor growth factor-beta activation pathway in a cell which comprises suppressing endogenous expression of an amino acid sequence depicted in SEQ ID NO:4.
- 69. (New) A method of screening for a modulator of Smurf activity which comprises detecting modulation of Smurf activity in the presence of a test compound relative to Smurf activity in the absence of the test compound.
- 70. (New) The method according to claim 69, wherein the Smurf activity is ubiquitination of a Smad polypeptide in a host cell.

- 71. (New) The method according to claim 69, wherein the Smurf activity is interaction of a Smurf WW domain with a PPYX domain of a Smad polypeptide.
- 72. (New) The method according to claim 71, wherein the test compound is screened for the ability to inhibit the interaction.
- 73. (New) An antibody which specifically binds to an amino acid sequence depicted in SEQ ID NO:2.
- 74. (New) An antibody which specifically binds to an amino acid sequence depicted in SEQ ID NO:4.

## **SUPPORT FOR THE CLAIMS**

CLAIM	EXAMPLES OF SUPPORT IN THE SPECIFICATION
37, 39, 41, 43	• p. 21, line 33 to p. 22, line 4
38, 42, 45, 46	<ul> <li>p. 4, lines 14-20</li> <li>p. 13, lines 17-19</li> <li>p. 14, lines 1-2</li> </ul>
40	• p. 24, lines 20-22
44	• p. 24, lines 20-22
49, 55	• p. 24, lines 20-22
47, 48, 53, 54	• p. 21, lines 23-32
50, 56	<ul> <li>p. 4, lines 26-28</li> <li>p. 17, line 32 to p. 18, line 26</li> <li>p. 23, line 35 to p. 24, line 2</li> </ul>
51, 52	• p. 14, lines 1-2
57, 59	<ul> <li>p. 24, lines 3-5</li> <li>p. 29, line 30 to p. 31, line 11</li> <li>p. 33, lines 20-24</li> </ul>
58, 60, 61, 62	<ul> <li>p. 28, lines 10-21</li> <li>p. 31, line 27 to p. 32, line 2</li> <li>p. 43, line 34 to p. 44, line 2</li> </ul>
63, 64	<ul> <li>p. 5, lines 1-3</li> <li>p. 44, lines 9-12</li> </ul>
65, 67	<ul> <li>p. 5, lines 4-7</li> <li>p. 13, lines 11-15</li> <li>p. 14, line 33 to p. 15, line 5</li> </ul>
66, 68	<ul> <li>p. 5, lines 7-10</li> <li>p. 19, lines 26-31</li> <li>p. 33, lines 6-9</li> </ul>
69	• p. 41, line 29 to p. 42, line 14

	• p. 44, lines 2-9
70	• p. 13, lines 13-14
	• p. 14, lines 21-24
	• p. 52, lines 21-23
71	• p. 13, lines 23-24
	• p. 14, lines 24-27
	• p. 53, lines 13-19
72	• p. 41, lines 29-34
73, 74	• p. 33, lines 10-16
	• p. 39, line 8 to p. 41, line 20